International expert consensus on immunotherapy for early-stage non-small cell lung cancer
- PMID: 36248334
- PMCID: PMC9554679
- DOI: 10.21037/tlcr-22-617
International expert consensus on immunotherapy for early-stage non-small cell lung cancer
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-617/coif). TH serves as an unpaid editorial board member of Translational Lung Cancer Research from January 2022 to December 2023. AR serves as an unpaid editorial board member of Translational Lung Cancer Research from November 2020 to October 2022. RAR serves as an unpaid editorial board member of Translational Lung Cancer Research from January 2022 to December 2023. MP serves as an unpaid editorial board member of Translational Lung Cancer Research from October 2021 to September 2023. RAR has been a consultant for Amgen, Ipsen Biopharmaceuticals, Novartis, Advanced Accelerator Applications, Curium Pharma, EMD Serono, Astra-Zeneca. He has also received research funding (to institution) from Merck & Co and Aadi Biosciences. He is also on the speaker bureaus for Ipsen Biopharmaceuticals and Astra-Zeneca. Mariano Provencio received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events and consulting fees from BMS, Astra Zéneca, MSD, Roche, Takeda and Pfizer. Jay M. Lee reports advisory board/consultant of Astrazeneca, Bristol Myers Squibb, Genentech, Novartis, Roche; research support from Genentech, Novartis; steering committee of Genentech, Novartis; speaker’s bureau of AstraZeneca, Genentech, Roche; stock from Moderna; patents of UCLA. Antonio Passaro received honoraria for consulting, advisory role or lectures from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Jansenn, Merck Sharp & Dohme, Roche Genentech, Novartis, MundiPharma, Daiichi Sankyo, eCancer and Medscape. TC reports speaker fees/honoraria from The Society for Immunotherapy of Cancer, Bristol Myers Squibb, Roche, Medscape, and PeerView; travel, food and beverage expenses from Dava Oncology; advisory role/consulting fees from AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck & Co., Genentech, and Arrowhead Pharmaceuticals; and institutional research funding from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim and EMD Serono. The other authors have no conflicts of interest to declare.
Similar articles
-
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2. J Immunother Cancer. 2018. PMID: 30012210 Free PMC article.
-
[Expert consensus on PD-L1 expression testing in non-small-cell lung cancer in China].Zhonghua Zhong Liu Za Zhi. 2020 Jul 23;42(7):513-521. doi: 10.3760/cma.j.cn112152-20200313-00202. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32842436 Chinese.
-
Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study.Pract Radiat Oncol. 2018 Mar-Apr;8(2):e71-e78. doi: 10.1016/j.prro.2017.10.008. Epub 2017 Dec 30. Pract Radiat Oncol. 2018. PMID: 29291965
-
Definition and assessment of high risk in patients considered for lobectomy for stage I non-small cell lung cancer: The American Association for Thoracic Surgery expert panel consensus document.J Thorac Cardiovasc Surg. 2021 Dec;162(6):1605-1618.e6. doi: 10.1016/j.jtcvs.2021.07.030. Epub 2021 Jul 29. J Thorac Cardiovasc Surg. 2021. PMID: 34716030
-
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.Expert Rev Anticancer Ther. 2018 Jan;18(1):63-70. doi: 10.1080/14737140.2018.1409624. Epub 2017 Nov 26. Expert Rev Anticancer Ther. 2018. PMID: 29168933 Free PMC article. Review.
Cited by
-
Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC.Cancers (Basel). 2024 Apr 23;16(9):1619. doi: 10.3390/cancers16091619. Cancers (Basel). 2024. PMID: 38730571 Free PMC article. Review.
-
The beginning of the perioperative immunotherapy era in early-stage non-small cell lung cancer.Transl Lung Cancer Res. 2023 Nov 30;12(11):2359-2365. doi: 10.21037/tlcr-23-470. Epub 2023 Nov 1. Transl Lung Cancer Res. 2023. PMID: 38090512 Free PMC article. No abstract available.
-
Association between pathologic response and survival after neoadjuvant therapy in lung cancer.Nat Med. 2024 Jan;30(1):218-228. doi: 10.1038/s41591-023-02660-6. Epub 2023 Oct 30. Nat Med. 2024. PMID: 37903504 Free PMC article.
-
Neoadjuvant chemoimmunotherapy cycle number selection for non-small cell lung cancer and clinical outcomes: a real-world analysis.Front Oncol. 2023 Sep 5;13:1200625. doi: 10.3389/fonc.2023.1200625. eCollection 2023. Front Oncol. 2023. PMID: 37731645 Free PMC article.
-
[Questions and Answers in Lung Cancer].Open Respir Arch. 2023 Sep 1;5(3):100264. doi: 10.1016/j.opresp.2023.100264. eCollection 2023 Jul-Sep. Open Respir Arch. 2023. PMID: 37727151 Free PMC article. Spanish.
References
-
- Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi 2019;41:19-28. - PubMed
Publication types
LinkOut - more resources
Full Text Sources